BRD9 inhibition could promote CSC differentiation or decrease cellular plasticity by increasing the epigenetic barriers that are necessary for the cells to dedifferentiate from nonstem cancer cells to CSC (Figure 2E). This evidence concerns the gene BRD9 and cancer.